Guisen Li

机构：University of Electronic Science and Technology of China, China Pharmaceutical University, National Medical Products Administration, Medicina · ORCID：0000-0003-1970-9979

发表论文 254 篇 · 总被引 3768 次 · h-index 31

代表论文

• Proteomics in pancreatic cancer (2025 · Biomarker Research · 被引 13)
• Glycosylation in kidney diseases (2025 · Precision Clinical Medicine · 被引 13)
• Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety (2025 · Clinical Kidney Journal · 被引 10)
• Smad3 Mediates Renal Fibrosis via GPX4-Dependent Ferroptosis (2025 · International Journal of Biological Sciences · 被引 8)
• Targeting ALOX5 ameliorates renal tubular injury in ischemia–reperfusion-induced acute kidney injury via inhibition of ferroptosis (2025 · Communications Biology · 被引 6)
• Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial (2025 · BMJ · 被引 6)